Figure 1.

Dasatinib notably suppresses RCC cell survival by inducing G1/S cell cycle arrest. (A) IC₅₀ values of FDA-approved kinase inhibitors in 6 RCC cell lines were assessed using an SRB assay. The data are represented as a heatmap drawn using R. (B) IC₅₀ values of dasatinib in different solid tumor types were assessed using an SRB assay. Bars, mean ± SD. (C-E) Caki-1 and 769-P cells were treated with DMSO or dasatinib for 24 h. The gene expression array was subjected to KEGG pathway analysis (C). Cell cycle distribution was analyzed by flow cytometry. Bars, mean ± SD (D). DNA replication capability was evaluated by EdU incorporation. Scale bar, 300 μm (E).